FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 203	10

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Olagunju Peter						2. Issuer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [TCRR]									k all app Direc	licable) tor er (give title	ng Person(s) to I 10% C Other below)		Owner (specify
(Last) (First) (Middle) C/O TCR2 THERAPEUTICS 100 BINNEY STREET						3. Date of Earliest Transaction (Month/Day/Year) 12/07/2022										Chief Tech	nical	,	
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(5.13)				n-Deriva	tive S	Secui	ritie	s Acq	uired,	Dis	posed of	, or B	enefi	cially	/ Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					tion	ion 2A. Deemed Execution Date,			3. Transaction Code (Instr.		4. Securities Acquired (ADisposed Of (D) (Instr. 3, 5)		red (A)	o) or 5. Amo 4 and Securit Benefic		ount of 6. ties (Cially (Dispute)		wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
							Code	v	Amount	(A) o (D)	Pric	е	Transa	ction(s) 3 and 4)			(111341. 4)		
Common											31	1,710		D					
Common	2022				S ⁽¹⁾		1,378	D	\$1	.282	30,332			D					
Common Stock 12/08/2						2022			S ⁽¹⁾		1,410	D	\$1	.253	253 28,922		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, or Exercise (Month/Day/Year) if any				4. Transaction Code (Instr 8)				6. Date Expirat (Month	ion Da		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In:	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						v	(A) (D)		Date Exercisable		Expiration Date	Amount or Number of Title Shares							

Explanation of Responses:

Remarks:

/s/ Margaret Siegel as Attorney-in-Fact

12/09/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.